PF-Atlas › Clinical Trials › NCT07519070

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis

HSK44459 · Phase 3

Registry ID

NCT07519070

Phase

Phase 3

Status

Not yet recruiting

Drug / intervention

HSK44459

Sponsor

Haisco Pharmaceutical Group Co., Ltd.

Start

2026-04-05

Enrollment

420

About this trial

This study aims to evaluate the efficacy and safety of HSK44459 tablets in patients with idiopathic pulmonary fibrosis (IPF).

View NCT07519070 on ClinicalTrials.gov →

Explore related

All HSK44459 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT07519070 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.